The highly selective RET inhibitors (e.g. selpercatinib and pralsetinib) have led to a paradigm change in the treatment of RET-mutated thyroid cancers, thanks to their strong efficacy and tolerable toxicity profile. The gene discussed is RET; the disease is thyroid gland carcinoma.